Regulatory update – GSK announces regulatory submission for albiglutide in Europe

GlaxoSmithKline plc (GSK) today announced the submission of a Marketing Authorisation Application (MAA) for albiglutide, with the proprietary name EPERZAN, to the European Medicines Agency (EMA).
Source: GSK news - Category: Pharmaceuticals Source Type: news